Multi-institutional observational study on the treatment of unresectable urothelial carcinoma in the era of combined immunotherapy

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-jRCT1050240231

Enrollment

1200

Registered

2025-01-06

Start date

2025-01-06

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Urothelial carcinoma

Interventions

None listed

Eligibility

Inclusion criteria

Inclusion criteria: Patients with unresectable or metastatic urothelial carcinoma who may be eligible for systemic drug therapy as first line treatment. A history of perioperative chemotherapy and adjuvant therapy is acceptable. Patients who have elected to receive no treatment due to their general condition or social background are also acceptable.

Exclusion criteria

Exclusion criteria: Not specified.

Design outcomes

Primary

Measure	Time frame
Overall survival for 1st line treatment	—

Secondary

Measure	Time frame
Selection of 1st line and Sequential Treatment Regimens Patient Background by 1st line and Sequential Treatment Regimen Progression-free survival for 1st line treatment Safety, including treatment-related adverse events	—

Contacts

Public ContactYuki Kita

Kyoto University Hospital

kitayuki@kuhp.kyoto-u.ac.jp+81-9094031731

Outcome results